Alpine Immune Sciences, Inc. (NASDAQ:ALPN) is expected to report second quarter earnings results, after market close, on Tuesday 11th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter income of $ 0.53 per share.
Looking ahead, the full year loss are expected at $ 0.04 per share on the revenues of $ 27.99 million.
Previous Quarter Performance
Alpine Immune Sciences, Inc. unfold loss for the first quarter of $ 0.30 per share, from the revenue of $ 1.09 million. The quarterly revenues up 2,080.00 percent compared with the same quarter last year. Street analysts expected Alpine Immune Sciences, Inc. to report loss of $ 0.47 per share on revenue of $ 0.38 million for the first quarter. The bottom line results beat street analysts by $ 0.17 or 36.17 percent, at the same time, top line results outshined analysts by $ 0.71 million or 186.84 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Alpine Immune Sciences, Inc.
Stock Performance
According to the previous trading day, closing price of ALPN was $ 10.40, representing a 407.32 % increase from the 52 week low of $ 2.05 and a 30.67 % decrease over the 52 week high of $ 15.00.
The company has a market capital of $ 246.80 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ALPN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Alpine Immune Sciences, Inc. will be hosting a conference call at 4:30 PM eastern time on 11th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.alpineimmunesciences.com
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
